Hindustan Bio Sciences Ltd (532041)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 31 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 24 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Hindustan Bio Sciences Ltd reported Q2 FY27 results on 31 Oct 2026: revenue ₹0.8 Cr, and net profit ₹0.3 Cr (against a loss a year earlier); the operating margin was 34.4%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.8 | — | — |
| செயல்பாட்டு லாபம் | ₹0.3 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| நிகர லாபம் | ₹0.3 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| EPS (₹) | 0.30 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| செயல்பாட்டு லாப வரம்பு | 34.4% | — | — |
- திருப்பம்: ஓராண்டுக்கு முன் நஷ்டத்திற்கு மாறாக லாபம்
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹0.3 கோடி லாபத்தில், ₹0.3 கோடி (91%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Hindustan Bio Sciences reported Q2 FY27 (quarter ended September 30, 2026) revenue from operations of Rs 82.21 lakh, compared to nil in Q1 FY27 and nil in Q2 FY26. Net profit stood at Rs 31.04 lakh for the quarter, recovering from a loss of Rs 11.29 lakh in the preceding quarter and a loss of Rs 5.85 lakh in the year-ago period. For H1 FY27, revenue reached Rs 82.21 lakh with a net profit of Rs 19.74 lakh. Additionally, Company Secretary and Compliance Officer Shailendra Vyas resigned effective October 31, 2026.
- Revenue from operations rebounded to Rs 82.21 lakh in Q2 compared to Rs 0.00 lakh in Q1
- Net profit turned positive at Rs 31.04 lakh versus a net loss of Rs 11.29 lakh in Q1
- Stock-in-trade purchases were Rs 46.13 lakh out of total expenses of Rs 54.00 lakh
- H1 FY27 net profit reached Rs 19.74 lakh against a net loss of Rs 4.45 lakh in H1 FY26
- Company Secretary & Compliance Officer Shailendra Vyas resigned effective October 31, 2026
Hindustan Bio Sciences Ltd has scheduled its Board of Directors meeting on October 31, 2026. The agenda includes the consideration and approval of the un-audited financial results for the quarter ended September 30, 2026. The micro-cap company (market cap of Rs 7 Cr) previously reported zero revenue and a net loss of Rs 0.11 Cr in the June 2026 quarter.
- Board meeting scheduled for October 31, 2026
- Agenda: Approval of un-audited financial results for the quarter ended September 30, 2026
- Filing made under Regulation 29(1)(a) of SEBI LODR Regulations, 2015
Hindustan Bio Sciences Limited held its 34th Annual General Meeting on September 30, 2026, with 39 shareholders present (4 promoter, 35 public). Key resolutions tabled included the adoption of FY26 financial statements, the reappointment of retiring director Smt. Uma Jampana, and a special resolution to consider a Scheme of Reduction of Share Capital. Voting was conducted via remote e-voting and physical poll, with results expected within 2 working days. The company has a tiny market cap of ₹7 Cr and recorded zero revenue in recent quarters.
- 34th AGM held on September 30, 2026, commencing at 10:00 AM and concluding at 10:45 AM
- Total of 12,039 shareholders recorded as of the record/book closure date
- 39 shareholders attended the physical meeting (4 promoters and 35 public members)
- Special resolution proposed to consider a Scheme of Reduction of Share Capital
Hindustan Bio Sciences' Board approved a Scheme of Capital Reduction under Section 66 of the Companies Act to write off Rs 1.13 Cr of accumulated losses (out of total accumulated losses of Rs 1.22 Cr). The scheme reduces paid-up equity capital from Rs 2.05 Cr (1,02,50,800 shares of Rs 2 face value) to Rs 0.92 Cr (46,12,860 shares of Rs 2 face value) by cancelling 56,37,940 shares pro-rata. Subsequently, the remaining shares will be consolidated 5:1 from Rs 2 face value to Rs 10 face value, resulting in a final capital base of 9,22,572 equity shares of Rs 10 each (an effective ratio of 9 shares of Rs 10 for every 100 shares of Rs 2 held).
- 56,37,940 equity shares of Rs 2 face value will be cancelled and extinguished on a pro-rata basis.
- Paid-up capital reduces from Rs 2,05,01,600 to Rs 92,25,720, setting off Rs 1,12,75,880 against accumulated losses of Rs 1,22,41,849.
- Shares will be consolidated from Rs 2 to Rs 10 face value; shareholders will receive 9 equity shares of Rs 10 for every 100 shares of Rs 2 held.
- Total outstanding shares shrink from 1,02,50,800 to 9,22,572 shares of Rs 10 each without altering relative percentage shareholding.
Hindustan Bio Sciences has scheduled a Board of Directors meeting on August 31, 2026, to consider and approve a draft Scheme of Reorganization/Rearrangement of Share Capital. The Board will also review the revised notice convening the company's 34th Annual General Meeting (AGM). In compliance with SEBI insider trading regulations, the trading window is closed from August 27, 2026, until 48 hours following the meeting. The micro-cap company currently operates with a market capitalization of ~Rs 7 Cr and a net worth of Rs 1 Cr.
- Board meeting convened for August 31, 2026, to consider a draft Scheme of Reorganization/Rearrangement of Share Capital.
- Board to review and approve the revised notice for the 34th Annual General Meeting.
- Trading window closed from August 27, 2026, until 48 hours post-meeting conclusion.
Hindustan Bio Sciences reported a complete halt in operational revenue for the quarter ended June 30, 2026, recording Rs 0.00 compared to Rs 32.19 Lakhs in the same period last year. The company posted a net loss of Rs 11.29 Lakhs, a sharp decline from the Rs 1.40 Lakh profit recorded in Q1 FY26. Total expenses of Rs 11.29 Lakhs were primarily driven by employee benefits and administrative costs, despite no trading activity. With a high debt-to-equity ratio of 2.83 and very low promoter holding of 12.2%, the lack of revenue is a significant concern for solvency.
- Revenue from operations dropped to Rs 0.00 from Rs 32.19 Lakhs in the year-ago quarter
- Net loss for the quarter stood at Rs 11.29 Lakhs versus a profit of Rs 1.40 Lakhs YoY
- Employee benefit expenses remained steady at Rs 5.72 Lakhs despite zero revenue generation
- The company's 34th Annual General Meeting (AGM) is scheduled for September 30, 2026
- Total comprehensive loss for the period matched the net loss at Rs 11.29 Lakhs
Hindustan Bio Sciences has scheduled a board meeting on July 31, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is currently in a fragile financial state with a small market capitalization of Rs 7 Cr and a high Debt-to-Equity ratio of 2.83. Investors should note that the company reported zero revenue in the most recent March 2026 quarter, making this upcoming earnings release critical for assessing business continuity. Promoter holding remains low at 12.19%, providing limited skin in the game.
- Board meeting scheduled for July 31, 2026, to approve results for the quarter ended June 30, 2026
- Company reported zero revenue and a net loss of Rs 0.12 Cr in the preceding March 2026 quarter
- Promoter holding is stagnant at a low level of 12.19% as of June 2026
- TTM revenue stands at just Rs 1 Cr against a debt of Rs 2 Cr
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
